Biovian has expanded its GMP QC laboratory facilities by 708 m2 to increase analytical capability. Expansion is fully deployed, FIMEA inspected and certified to comply GMP regulations. After expansion Biovian has 3 400 m2 GMP certified facilities for manufacturing authorization for investigational use (including biopharmaceuticals, gene therapy and sterile products). Commercial manufacturing license is certified for small volume sterile liquids and gene therapy products.
The latest expansion brings more capacity to serve customers manufacturing projects. We are excited to be able to add this considerable additional analytical capacity to Biovian’s already strong analytical GMP offering, says Dr. Knut Ringbom, CEO of Biovian. With this expansion we will be able to cater the entire analytical process from early development to fully validated analyses, he continues.